AVEO Pharmaceuticals, Inc.(NASDAQ : AVEO)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.29%||79.74||0.9%||$563.79m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.06%||126.75||2.0%||$276.96m|
|REGN||Regeneron Pharmaceuticals, Inc.||2.50%||343.30||2.7%||$275.56m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.97%||175.66||1.9%||$265.02m|
|A||Agilent Technologies, Inc.||-0.43%||69.88||1.5%||$176.42m|
|EXAS||Exact Sciences Corporation||0.92%||52.57||25.7%||$143.36m|
|SRPT||Sarepta Therapeutics, Inc.||-0.37%||80.92||16.7%||$123.27m|
|BLUE||Bluebird Bio, Inc.||-6.92%||199.80||15.8%||$122.80m|
|BMRN||BioMarin Pharmaceutical Inc.||0.63%||84.10||4.4%||$104.37m|
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its products include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. It focuses on the development of Tivozanib, in North America as a treatment for renal cell carcinoma. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.